Pneumagen Company

Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology.

Last Funding Type: Venture - Series Unknown
Headquarters: Saint Andrews, Fife, United Kingdom
Founded Date: 2016
Investor Type: For Profit
Total Funding: £4M
Technology: Anti-infective Drugs
Employee Number: 1-10
Estimated Revenue: $1M to $10M
Investors Number: 2
Industry: PharmTech